title: Biologics in rheumatoid arthritis--recommendations for Swiss practice.
abstract: The new paradigm of therapy in rheumatoid arthritis is to aim toward early and complete remission, using a larger use of conventional DMARDs and biologic agents. The present recommendations were established through a consensus to help practitioners in their daily use of those agents, to reflect the current "best practice" in Switzerland.
authors.affiliation: Department of Rheumatology, University Hospital Lausanne, Switzerland. jean.dudler@chuv.ch
authors.forename: Jean
authors.initials: J
authors.lastname: Dudler
authors.forename: Burkhard
authors.initials: B
authors.lastname: Möller
authors.forename: Beat A
authors.initials: BA
authors.lastname: Michel
authors.forename: Peter M
authors.initials: PM
authors.lastname: Villiger
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D012074:Remission Induction; D013557:Switzerland; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; D008727:Methotrexate